No abstract

No abstract

<b><i>Introduction:</i></b> <i>MIR155HG</i> has been found to play an important role in malignant tumors, but little research has been done on its association with esophageal cancer (ESCC). The aim of this study was to investigate the relationship between <i>MIR155HG</i> polymorphisms and ESCC susceptibility in the Chinese Han population. <b><i>Methods:</i></b> 511 ESCC patients and 487 healthy controls were selected for this study. All subjects were genotyped using the Agena MassARRAY platform. We assessed the association between seven single nucleotide polymorphisms (SNPs) of the <i>MIR155HG</i> and ESCC risk by genetic model analysis. The false discovery rate (FDR) test and Bonferroni correction were usually used to detect false positives for the results. Meanwhile, the interaction between SNPs was analyzed by multifactor dimensionality reduction software to predict the ESCC risk. <b><i>Results:</i></b> The C allele of rs4143370 and the A allele of rs34904192 in <i>MIR155HG</i> can increase the risk of ESCC (odds ratio (OR) = 1.33, <i>p</i> = 0.024; OR = 1.30, <i>p</i> = 0.013). Furthermore, rs4143370 and rs34904192 were associated with an increased risk of ESCC. Stratified analysis showed that <i>MIR155HG</i> SNPs (rs4143370 and rs34904192) significantly increased ESCC risk in males. <i>MIR155HG</i> SNPs (rs4143370, rs34904192, and rs928883) were also strongly associated with an increased risk of ESCC in people aged &#x3e;64 years. In addition, haplotype analysis of the seven SNPs of the <i>MIR155HG</i> showed that the CC haplotype was associated with ESCC risk (OR = 1.34, <i>p</i> = 0.024). <b><i>Conclusion:</i></b> This study revealed that <i>MIR155HG</i> SNPs were associated with an increased risk of ESCC. The results provided clues for clarifying the role of MIR155HG in ESCC.

Sleeve lobectomy is an uncommon thoracic surgical procedure. Nonetheless, it is an accepted treatment option to avoid pneumonectomy in patients with centrally, locally advanced non-small cell lung cancer. In appropriately selected patients, the outcome of sleeve lobectomy is equivalent to pneumonectomy with comparable recurrence rates, with less perioperative morbidity, improved functional outcomes, and superior quality of life post-surgery. According to the National Comprehensive Cancer Network (NCCN)or Chinese Society of Clinical Oncology (CSCO) guidelines, neoadjuvant chemotherapy has become the standard treatment regimen in patients with stage N2 non-small cell lung cancer, despite the high risk of associated complications, due to its proven efficacy in improving prognosis in these patients. Here we report a case of a central squamous carcinoma in the upper lobe of the right lung. Bronchoscopy revealed rough and uplifted mucosa in the right upper bronchus and a narrow lumen. The patient was diagnosed with squamous carcinoma of the right upper lobe with subcarinal lymph node metastasis, and no distant metastasis (clinical stage cT4N2M0, IIIB). The Multi-Disciplinary Treatment (MDT)team recommended 2 cycles of neoadjuvant chemotherapy. Although the size of the tumor had reduced significantly after the second cycle, as observed on the CT images, it was still close to orifice of the right upper bronchus. So our surgical team performed a right upper sleeve lobectomy with 3-port thoracoscope. The patient recovered very well after the procedure. Our first experience of bronchial reconstruction after neoadjuvant chemotherapy showed no increased morbidity and mortality, making it a technically safe and feasible approach.

No abstract